Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RARA | P10276 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | TACR2 | P21452 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983507 | 0.98 | HSD17B10 (0.64) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL5542220 | 0.98 | HSD17B10 (0.64) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL3090093 | 0.98 | HSD17B10 (0.64) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL17022435 | 0.98 | HSD17B10 (0.64) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL5544425 | 0.98 | HSD17B10 (0.64) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL28518716 | 0.98 | HSD17B10 (0.64) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL6754529 | 0.94 | RARB (0.55) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL980959 | 0.94 | RARB (0.55) | HSD17B10TSHRRARBALDH1A1MEN1 | |
| SCHEMBL58197 | 0.87 | ESR1 (0.54) | HSD17B10TSHRRARBALDH1A1KDM4E | |
| SCHEMBL31549867 | 0.87 | RARB (0.68) | HSD17B10TSHRRARBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020081840-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | Magenta Therapeutics Inc. (US) | 2020-04-23 | — | — | WO | claimed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| EP-0107116-B1 | DICYANOBENZENES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-08-27 | — | — | EP | claimed |
| EP-3874027-A2 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | Magenta Therapeutics, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2020081840-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | Magenta Therapeutics Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2513125-A1 | METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS | BASF SE (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-0120717-B1 | ANTHRAQUINONE DYES AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THE DYES | MITSUBISHI KASEI CORPORATION (JP) | 1988-12-07 | — | — | EP | disclosed |
| US-4610804-A | Anthraquinone dyes and liquid crystal compositions including the same | HITACHI, LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4528113-A | Anthraquinone dye and liquid crystal composition containing the dye | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1985-07-09 | — | — | US | disclosed |
| US-4507221-A | Anthraquinone dye and liquid crystal composition containing the same | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
| EP-0120717-A2 | Anthraquinone dyes and liquid crystal compositions containing the dyes | MITSUBISHI KASEI CORPORATION (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0120463-A2 | Anthraquinone dyes and liquid crystal compositions including the same | HITACHI, LTD. (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0098736-A2 | Anthraquinone dyes and liquid crystal compositions containing the dyes | MITSUBISHI KASEI CORPORATION (JP) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | HSD17B10 2221/4885TSHR 478/4885RARB 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.